Publications by authors named "Nonkululeko B Mzindle"
Article Synopsis
- Vervet monkeys are being researched as a cost-effective model for studying infectious diseases, particularly HIV immunization, due to their strong antibody responses and availability in low-resourced areas.
- In an experiment, three groups of vervet monkeys were immunized with different HIV envelope trimer immunogens, resulting in robust binding antibodies and successful antibody-dependent cellular phagocytosis.
- While the monkeys developed strong neutralizing antibody responses, the effectiveness of neutralization was limited, highlighting the need for further investigation into how this model compares to others for HIV research.
We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.
View Article and Find Full Text PDFBackground: We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.
View Article and Find Full Text PDFAntibodies with the same variable region can exist as multiple isotypes with varying neutralization potencies, though the mechanism for this is not fully defined. We previously isolated an HIV-directed IgA1 monoclonal antibody (mAb), CAP88-CH06, and showed that IgA1 and IgG3 isotypes of this antibody demonstrated enhanced neutralization compared to IgG1. To explore the mechanism behind this, hinge region and constant heavy chain (CH1) chimeras were constructed between the IgA1, IgG3 and IgG1 mAbs and assessed for neutralization activity, antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC).
View Article and Find Full Text PDF